A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke
Latest Information Update: 21 Oct 2021
At a glance
- Drugs Natalizumab (Primary)
- Indications Stroke
- Focus Proof of concept; Therapeutic Use
- Acronyms ACTION
- Sponsors Biogen
- 21 Mar 2020 Results (n=159) assessing exposure response analysis of natalizumab in subjects with acute Ischemic Stroke, presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 19 Feb 2016 Primary endpoint of relative change in infarct growth from baseline to day 5 assessed by MRI has not been met, according to results presented at the 41st International Stroke Conference.